ZA200105406B - Method of producing cyclene. - Google Patents
Method of producing cyclene. Download PDFInfo
- Publication number
- ZA200105406B ZA200105406B ZA200105406A ZA200105406A ZA200105406B ZA 200105406 B ZA200105406 B ZA 200105406B ZA 200105406 A ZA200105406 A ZA 200105406A ZA 200105406 A ZA200105406 A ZA 200105406A ZA 200105406 B ZA200105406 B ZA 200105406B
- Authority
- ZA
- South Africa
- Prior art keywords
- hours
- cyclene
- process according
- solvent
- reaction
- Prior art date
Links
- RRBYUSWBLVXTQN-UHFFFAOYSA-N tricyclene Chemical compound C12CC3CC2C1(C)C3(C)C RRBYUSWBLVXTQN-UHFFFAOYSA-N 0.000 title claims abstract description 43
- RRBYUSWBLVXTQN-VZCHMASFSA-N tricyclene Natural products C([C@@H]12)C3C[C@H]1C2(C)C3(C)C RRBYUSWBLVXTQN-VZCHMASFSA-N 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 73
- 238000006243 chemical reaction Methods 0.000 claims description 46
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 42
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 36
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 34
- 239000002904 solvent Substances 0.000 claims description 25
- 238000010992 reflux Methods 0.000 claims description 23
- 238000001704 evaporation Methods 0.000 claims description 21
- 230000008020 evaporation Effects 0.000 claims description 21
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims description 19
- 229940015043 glyoxal Drugs 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 11
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 11
- KLKFAASOGCDTDT-UHFFFAOYSA-N ethoxymethoxyethane Chemical compound CCOCOCC KLKFAASOGCDTDT-UHFFFAOYSA-N 0.000 claims description 11
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 8
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 5
- 239000002168 alkylating agent Substances 0.000 claims description 5
- 229940100198 alkylating agent Drugs 0.000 claims description 5
- 239000003586 protic polar solvent Substances 0.000 claims description 5
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 claims description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- GBBZLMLLFVFKJM-UHFFFAOYSA-N 1,2-diiodoethane Chemical compound ICCI GBBZLMLLFVFKJM-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 3
- 239000000920 calcium hydroxide Substances 0.000 claims description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 3
- 239000007859 condensation product Substances 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- QJNULWKDWXIXLJ-UHFFFAOYSA-N 1,2-bis(methylsulfonyl)ethane Chemical compound CS(=O)(=O)CCS(C)(=O)=O QJNULWKDWXIXLJ-UHFFFAOYSA-N 0.000 claims description 2
- ATPZFDFVYMLXFX-UHFFFAOYSA-N 1-methyl-4-[2-(4-methylphenyl)sulfonylethylsulfonyl]benzene Chemical compound C1=CC(C)=CC=C1S(=O)(=O)CCS(=O)(=O)C1=CC=C(C)C=C1 ATPZFDFVYMLXFX-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 2
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 claims description 2
- 239000002370 magnesium bicarbonate Substances 0.000 claims description 2
- 235000014824 magnesium bicarbonate Nutrition 0.000 claims description 2
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 2
- 239000003880 polar aprotic solvent Substances 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- 238000006482 condensation reaction Methods 0.000 claims 2
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 235000010216 calcium carbonate Nutrition 0.000 claims 1
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 238000005580 one pot reaction Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 21
- 238000003756 stirring Methods 0.000 description 21
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 15
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000013067 intermediate product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011575 calcium Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CASDNPHWJOQUQX-UHFFFAOYSA-N 1-benzylaziridine Chemical compound C=1C=CC=CC=1CN1CC1 CASDNPHWJOQUQX-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010959 commercial synthesis reaction Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- OAEGRYMCJYIXQT-UHFFFAOYSA-N dithiooxamide Chemical compound NC(=S)C(N)=S OAEGRYMCJYIXQT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- RYHQMKVRYNEBNJ-BMWGJIJESA-K gadoterate meglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 RYHQMKVRYNEBNJ-BMWGJIJESA-K 0.000 description 1
- DPNNNPAKRZOSMO-UHFFFAOYSA-K gadoteridol Chemical compound [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- RTWNYYOXLSILQN-UHFFFAOYSA-N methanediamine Chemical compound NCN RTWNYYOXLSILQN-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000039 preparative column chromatography Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Tyre Moulding (AREA)
- Steering Devices For Bicycles And Motorcycles (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Seeds, Soups, And Other Foods (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a novel one-pot method of producing cyclene.
Description
Process for the Production of Cyclene
The invention relates to the subject that is characterized in the claims, i.e., a new process for the production of cyclene.
Cyclene (1,4,7,10-tetraazacyclododecane) is a frequently used starting material in the production of macrocyclic complexing agents and is mainly used in the area of nuclear resonance tomography as a ligand for gadolinium. Two ~ preparations are already commercially available with ProHance‘® of Bristol-Myers-Squibb and Dotarem®® of Guerbet. Special research and development projects also use cyclene as a starting material. There is therefore a need for an easy and economical process for the production of this educt.
One of the first published processes (Richman and Atkins, J.
Am. Chem. Soc. 1974, 96, p. 2268) employs the cyclization of a sodium bis-sulfonamide with a corresponding functionalized diethylene sulfonamide. In their synthesis, Weisman and Reed (J.
Org. Chem. 1996, 61, pp. 5186-5187) use the reaction of a bis- thioimidoester with triethylenetetramine for the creation of a tricyclic bis-imine, which is ultimately hydrolyzed to cyclene after reduction.
The processes of V. Panetta et al. (Tetrahedron Lett. 1992,
Vol. 33, No. 38, pp. 5505-5508), which perform a cyclization of a tetra-trifluoromethanesulfonic acid amide of triethylenetetramine with 1,2-dibromoethane, follow a more indirect approach to cyclene. The last reaction step comprises the release of cyclene. The process of the Nycomed Company (WO 96/28433) after the production of tribenzylcyclene is also dependent on such a procedure. The synthesis is accomplished by the reaction of a suitable triamine with a monoamine or the two suitable diamines.
The process that is disclosed in DE 19608307 and that contains a tetramerization of N-benzylaziridine as a key step also results in tetrabenzylcyclene.
As described in WO 97/31005 and US 5,587,451, the Dow
Chemical Company uses a bis-imidazoline that starts from triethylenetetramine as an intermediate product. The rings in the tetracyclic intermediate product are closed with 1,2- dibromoethane. The subsequent hydrolysis releases the cyclene. : As described in WO 97/49691, the Bracco Company uses a direct approach to cyclene, which starts with the condensation of triethylenetetramine with glyoxal -- which was already disclosed by Weisman et al. (Tetrahedron Lett. 1980, Vol. 21, pp. 335-338).
Then, the latter is converted into a tetracyclic intermediate compound by reaction with 1,2-dibromoethane. The removal of the ethylene bridge that connects the four heteroatoms is carried out by oxidation with bromine with subsequent hydrolysis (or else by hydrolysis with a primary diamine, WO 98/49151). The total yield is indicated with 25%.
1) Ca(OH), / H,0 BrCH,CH,Br /
H \ H ) Ca(OH), / Hy /\ 2CHy \
NON 2) Glyoxal Ne _N Na,CO5 / DMAC N._N von LL] Twemms LX ° 0, °
C.. L.. 5°C 3h.75% NN 80°C 6h 45% NTN . I LJ
R H H
Bry / Hy0 0 2Br NaOH / Hy0 HO \ H pH 4.5 Nao oN pH 14 NN
LX | wm LJ 25°C 18h NY 185°C 15 bar NN + o, ’ N \ 5h 68% HL CH
Diagram 1: Synthesis Sequence of the Bracco Company (WO 97/49691)
The synthesis that is disclosed in WO 96/28432 of the
Nycomed Company resembles the above-described synthesis, with the decisive difference being the hydrolysis of the central ethylene bridge. Here, the reaction is achieved by addition of hydroxylamine in an ethanolic solution while being heated. The : total yield for this reaction sequence is approximately 45%.
BrCH,CHABr/
H \ H Glyoxal / [1 22 [0 °N NZ EtOH N N DMF N N meme LX) oo [[X]
Ce L.. 20°C 20h 75% N N 20°C 20h 70% N N '
L J
NH,OH * HCI Ho [ \ HB
EtOH o 7] 90°C 18h N N
H \__J 'H
Diagram 2: Synthesis Sequence of the Nycomed Company (WO : 96/28432) : Evaluation of the Process:
The process according to WO 97/49691, supported by experimental reworking, has some decisive drawbacks, which are summarized briefly below:
The production of the tricyclic compound cannot be reproduced as described, since: -- The calcium hydroxide cannot be quantitatively separated. -- Larger amounts of water must be distilled off. -- The product does not accumulate as an oil, as indicated.
The purification of the tetracyclic compound is very expensive: -- The extraction of the product from a solid reduces the yield.
Hydrolysis into cyclene has proven to be very difficult: -- An autoclave reaction must be performed at pH = 14 and at 185°C. -- The product crystallizes poorly and with heavy contamination from the reaction solution.
The process according to WO 96/28432 also gives rise to criticism. The basic drawbacks are listed below: -- All synthesis stages have long stirring times. -- The purification of the tetracyclic compound is carried out via a preparative column chromatography. -- The hydrolysis to cyclene lasts for a very long time, : and the indicated purification method does not yield the product in the desired purity.
All other processes comprise multistage synthesis sequences, in which intermediate products are isolated, which generally is time-consuming and raw material-intensive. = The process of
Weismann and Reed is ruled out for commercial synthesis, since it is dependent on dithiooxamide (about DM 400/100 g) as one of the starting materials. In the process of Richman and Atkins as well as V. Panetta et al., correspondingly protected amines must first be prepared. After the reaction has been completed, as also in the process of the Dow Chemical Company, Nycomed (WO 96/28433) and Schering (DE19608307), the cleavage of these protective groups is necessary as an additional reaction step, which produces a poorer material balance relative to the desired product. In the case of tetramerization of benzylaziridine, it is necessary to work with large amounts of carcinogenic substances.
A profitable process should use raw materials that are as reasonably priced, as environmentally safe and as easily accessible as possible. The reaction times should also be short and should occur with little energy use. Moreover, the amounts c of material during the overall synthesis should be as small as possible.
This object is achieved by this invention. "It has been found that a process for the production of cyclene _ H. ’ — y
ON N
CUNON
H __. H characterized in that in a single-pot process, triethylenetetramine is reacted with 40% glyoxal at 20°C to 80°C in a polar, protic solvent, preferably methanol, ethanol, isopropanol, butanol, glycol, water or mixtures thereof, especially preferably ethanol, within 4 to 40 hours, preferably to 20 hours; after the solvent has been removed, the intermediate tricyclic compound that is thus formed is alkylated to the two secondary amine-nitrogens with a 1,2-difuntionalized alkylating agent X(CH,),X, in which X stands for a nucleofuge : group, preferably with 1,2-dibromoethane, 1,2-dichloroethane, 1,2-ditosylethane, 1,2-dimesylethane or 1,2-diiodoethane, especially preferably with 1,2-dichloroethane in a polar aprotic solvent, preferably in N,N-dimethylformamide (DMF), N,N- dimethylacetamide (DMAC), N-methylpyrrolidone (NMP), tetramethyl urea, formamide or dimethylpropylene urea (DMPU), especially preferably in DMF, optionally in the presence of an auxiliary
. : base, preferably sodium carbonate, potassium carbonate, calcium : carbonate, sodium bicarbonate, potassium hydrogen carbonate, magnesium carbonate, magnesium hydrogen carbonate, lithium hydroxide or lithium carbonate, especially preferably without an auxiliary base, at 20 to 120°C, preferably 30 to 70°C, within 2 } to 24 hours, preferably 6 to 10 hours; after the solvent has been removed, the thus obtained condensation product is treated with hydrazine hydrate in a polar protic solvent, preferably methanol, ethanol, isopropanol, butanol, glycol, water and/or mixtures thereof, especially preferably ethanol, at a pH of 3 to 6, preferably 3 to 4, 12 to 48 hours, preferably 25 to 35 hours, at reflux temperature; then the cyclene is released from the cyclene salt by adding a base, preferably sodium hydroxide, potassium hydroxide, calcium hydroxide or a basic ion exchanger, especially preferably sodium hydroxide and potassium hydroxide, and after the reaction solution is evaporated to the dry state, it is isolated, surprisingly enough achieves the above-mentioned object.
The isolation of the cyclene is preferably carried out by crystallization from toluene, trifluoromethylbenzene or diethoxymethane, whereby the latter is especially preferred.
By way of example, diagram 3 again sheds light on the process of the synthesis according to the invention: 1) Glyoxal /EtOH 20°C 20h :
H — H 2) CICH,CH,CI /IDMF H H
Noy 40°C 8h NS Vy
N N . r 7 —_—> NNN
R - }
NH, “NH, 3) HN-NH," H,0 “yn _ pH 4 / HCI PAUAN
TETA Reflux 30h H | S—; H 4) KOH pH 13 So 5) DEM 50 - 65% von TETA : [Key:] von = of
Advantages of the Process:
The process for the production of cyclene according to the invention has considerable advantages relative to the previous processes due to its design as a single-pot process. -- No time-intensive and raw material-intensive isolating steps of the intermediate products are necessary.
-- The reaction with amine is carried out without generating considerable amounts of by-products. : -- The raw materials are reasonably priced and easily accessible. -- Few wastes accumulate. -- The total synthesis time is short. -- A new, economical purification process for cyclene is used. - The yield is higher than in the process of the prior art.
The following example is used for a more detailed explanation of the subject of the invention.
Example 1 1,4,7,10 Tetraazacyclododecane (= cyclene): 50 g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of ethanol and mixed with 39 ml of 40% glyoxal in water (0.342 mol) at room temperature. After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil, which is taken up in 400 ml of dimethylformamide and mixed with 81.2 ml (101.5 g = 1.026 mol) of 1,2-dichloroethane, is obtained.
After 8 hours of stirring at 40°C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to about pH = 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g = 3.42 mol) of hydrazine oo hydrate is added to this reaction solution at room temperature, and it is heated under reflux for 30 hours. The reaction solution is set at pH = 13 with solid potassium hydroxide. The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed. The residue is mixed with 25 g of activated carbon and 100 ml of formaldehyde diethylacetal, and it is heated under reflux for some time before the hot solution is filtered through a membrane. After the solution is cooled, the product is isolated by filtration. 38.3 g of cyclene (0.222 mol = 65% of theory) is obtained as a crystalline solid.
Example 2 1,4,7,10-Tetraazacyclododecane (= cyclene) 50 g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of ethanol and mixed at room temperature with 39 ml of 40% glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of dimethylformamide and mixed with 88.5 ml (192.8 g = 1.026 mol) of 1,2-dibromoethane.
After 6 hours of stirring at 40°C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH = 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g = 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature,
and it is heated under reflux for 30 hours.
The reaction.
solution is set at pH = 13 with solid potassium hydroxide.
The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the i solvent is removed again in a vacuum.
The residue is mixed with g of activated carbon and 150 ml of formaldehyde diethylacetal, and it is heated under reflux for some time before the hot solution is filtered through a membrane.
After the solution is cooled, the product is isclated by filtration. 39.5 g of cyclene (67% of theory) is obtained as a crystalline solid.
Example 3 1,4,7,10-Tetraazacyclododecane (= cyclene) 50 g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of ethanol and mixed at room temperature with 39 ml of 40% glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which is then taken up in 400 ml of dimethylformamide and is mixed with 82.6 ml (274.8 g = 1.026 mol) of 1,2-diiodoethane. After 5 hours of stirring at 40°C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH = 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g = 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature, and it is heated under reflux for 30 hours. The reaction
BN solution is set at pH = 13 with solid potassium hydroxide. The : reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed again in a vacuum. The residue is mixed with g of activated carbon and 150 ml of formaldehyde diethylacetal, and it is heated under reflux for some time before the hot solution is filtered through a membrane. After the solution is cooled, the product is isolated by filtration. 37.1 g of cyclene (63% of theory) is obtained as a crystalline solid.
Example 4 1,4,7,10-Tetraazacyclododecane (= cyclene) : 50 g of triethylenetetramine (0.342 mol) is dissolved in 1 ml of methanol and mixed at room temperature with 39 ml of 40% glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of dimethylformamide and mixed with 81.2 ml (101.5 g = 1.026 mol) of 1,2-dichlorocethane.
After 8 hours of stirring at 40°C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH = 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g = 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature, and it is heated under reflux for 30 hours.
The reaction solution is set at pH = 13 with solid potassium hydroxide.
The : : reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed again in a vacuum.
The residue is mixed with g of activated carbon and 150 ml of formaldehyde diethylacetal, and it is heated under reflux for some time before the hot solution is filtered through a membrane.
After the solution is cooled, the product is isolated by filtration. 37.7 g of cyclene (64% of theory) is obtained as a crystalline solid.
Example 5 1,4,7,10-Tetraazacyclododecane (= cyclene) 50 g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of ethanol and mixed at room temperature with 39 ml of 40% glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of dimethyl acetamide and is mixed with 81.2 ml (101.5 g = 1.026 mol) of 1,2- - dichloroethane.
After 8 hours of stirring at 40°C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH = 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g = 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature and heated under reflux for 30 hours.
The reaction solution is set at pH = 13 with solid potassium hydroxide.
The reaction : solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed again in a vacuum.
The residue is mixed with 25 g of activated carbon and 150 ml of formaldehyde diethylacetal and heated under reflux for some time before the hot solution is filtered through a membrane.
After the solution is cooled, the product is isolated by filtration. 37.7 g of cyclene (64% of theory) is obtained as a crystalline solid.
Example 6 1,4,7,10-Tetraazacyclododecane (= cyclene) 50 g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of ethanol and mixed at room temperature with 39 ml of 40% glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of tetramethylurea and mixed with 81.2 ml (101.5 g = 1.026 mol) of 1,2- dichloroethane.
After 8 hours of stirring at 40°C, it is concentrated by evaporation in a vacuum, the residue is taken up oo in 400 ml of ethanol and acidified to pH = 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g = 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature oo and heated under reflux for 30 hours.
The reaction solution is set at pH = 13 with solid potassium hydroxide.
The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is again . removed in a vacuum.
The residue is mixed with 25 g of activated carbon and 150 ml of formaldehyde diethylacetal, and it is heated under reflux for some time before the hot solution is filtered through a membrane.
After the solution is cooled, the product is isolated by filtration. 37.1 g of cyclene (63% of theory) is obtained as a crystalline solid.
Example 7 1,4,7,10-Tetraazacyclododecane (= cyclene) 50 g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of ethanol and mixed at room temperature with 39 ml of 40%
glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of tetramethylurea and mixed with 88.5 ml (192.8 g = 1.026 mol) of 1,2-
dibromoethane.
After 6 hours of stirring at 40°C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH = 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g = 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature and heated under reflux for 30 hours.
The reaction solution is set at pH = 13 with solid potassium hydroxide.
The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed again in a vacuum.
The residue is mixed with 25 g of activated carbon and 150 ml of formaldehyde diethylacetal and heated under reflux for some time before the hot solution is filtered through a membrane.
After the solution is cooled, the product is isolated by filtration. 37.6 g of cyclene (64%
measured) 1s obtained as a crystalline solid.
Example 8 1,4,7,10-Tetraazacyclododecane (= cyclene) 50 g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of methanol and mixed at room temperature with 39 ml of 40% glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of dimethylformamide and mixed with 88.5 ml (192.8 g = 1.026 mol) of 1,2-dibromoethane. After 6 hours of stirring at 20°C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH = 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g = 3.42 mol) of hydrazine hydrate is added to this reaction solution and heated under reflux for 30 hours. The reaction solution is set at pH = 13 with solid potassium hydroxide. The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up.
Co once more in 100 ml of ethanol, and the solvent is removed again in a vacuum. The residue is mixed with 25 g of activated carbon and 150 ml of formaldehyde diethylacetal and heated under reflux for some time before the hot solution is filtered through a membrane. After the solution is cooled, the product is isolated by filtration. 35.9 g of cyclene (61% of theory) is obtained as a crystalline solid.
Example $S 1,4,7,10-Tetraazacyclododecane (= cyclene) 50 g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of ethanol and mixed at room temperature with 39 ml of 40% glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of dimethylformamide and mixed with 81.2 ml (101.5 g = 1.026 mol) of 1,2-dichloroethane.
After 8 hours of stirring at 40°C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH = 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g = 3.42 mol) of hydrazine hydrate is added at room temperature to this reaction solution, and then it is heated under reflux for 30 hours.
The reaction solution is set at pH = 13 with solid potassium hydroxide.
The reaction solution is subsequently concentrated by evaporation in. a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed again in a vacuum.
The residue is mixed with g of activated carbon and 200 ml of toluene and heated under reflux for some time before the hot solution is filtered through a membrane.
After the solution is cooled, the product is isolated by filtration. 35.8 g of cyclene (61% of theory) is obtained as a crystalline solid.
Example 10 1,4,7,10-Tetraazacyclododecane (= cyclene) 50 g of triethylenetetramine (0.342 mol) is dissolved in 1 1 of 2-propanol and mixed at room temperature with 39 ml of 40% glyoxal in water (0.342 mol). After 20 hours of stirring, the solvent is distilled off in a vacuum, and an orange-colored oil is obtained, which then is taken up in 400 ml of dimethylformamide and mixed with 81.2 ml (101.5 g = 1.026 mol) of 1,2-dichloroethane.
After 8 hours of stirring at 40°C, it is concentrated by evaporation in a vacuum, the residue is taken up in 400 ml of ethanol and acidified to pH = 3-4 with 37% aqueous hydrochloric acid. 166 ml (171 g = 3.42 mol) of hydrazine hydrate is added to this reaction solution at room temperature and heated under reflux for 30 hours.
The reaction solution is set at pH = 13 with solid potassium hydroxide.
The reaction solution is subsequently concentrated by evaporation in a vacuum, taken up once more in 100 ml of ethanol, and the solvent is removed again in a vacuum.
The residue is mixed with 25 g of activated carbon and 150 ml of formaldehyde diethylacetal and heated under reflux for some time before the hot solution is filtered through a membrane.
After the solution is cooled, the product is isolated by filtration. 37.2 g of cyclene (63% of theory) is obtained as a crystalline solid.
Claims (12)
1. Process for the production of cyclene BRA C0 ed " “H characterized in that in a single-pot process, triethylenetetramine is reacted with 40% glyoxal at 20°C to 80°C in a polar, protic solvent within 4 to 40 hours; after the solvent has been removed, the intermediate tricyclic compound that is thus formed is alkylated to the two secondary amine- nitrogens with a 1,2-difunctionalized alkylating agent X(CH,),X, in which X stands for a nucleofuge group, in a polar aprotic : solvent, optionally in the presence of an auxiliary base, at 20 i to 120°C within 2 to 24 hours; after the solvent has been removed, the thus obtained condensation product is treated with hydrazine hydrate in a polar protic solvent at a pH of 3 to 6 within 12 to 48 hours at reflux temperature; then the cyclene is released from the cyclene salt by adding a base, and after the : reaction solution is evaporated to the dry state, it is isolated.
2. Process according to claim 1, wherein methanol, ethanol, isopropanol, butanol, glycol, water or mixtures thereof are used as polar protic solvents. :
3. Process according to claim 1, wherein N,N- dimethylformamide (DMF), N,N-dimethylacetamide (DMAC), N-
methylpyrrolidone (NMP), tetramethylurea, formamide or dimethylpropylene urea (DMPU) is used as a polar aprotic solvent.
4. Process according to claim 1, wherein 1,2-dibromoethane, 1,2-dichloroethane, 1,2-ditosylethane, 1,2-dimesylethane or 1,2- diiodoethane is used as an alkylating agent X(CH,).X.
5. Process according to claim 1, wherein sodium carbonate, potassium carbonate, calcium carbonate, sodium bicarbonate, potassium hydrogen carbonate, magnesium carbonate, magnesium hydrogen carbonate, lithium hydroxide or lithium carbonate is used as an auxiliary base that is optionally used in the condensation reaction with the 1,2-difunctionalized alkylating agent X (CH) X.
6. Process according to claim 1, wherein sodium hydroxide, potassium hydroxide, calcium hydroxide or a basic ion exchanger is used as a base to release cyclene.
7. Process according to claim 1, wherein the reaction of triethylenetetramine is performed with glyoxal at 20 to 40°C within 15 to 20 hours.
8. Process according to claim 1, wherein the condensation reaction is performed with the 1,2-difunctionalized alkylating agent X(CH,),X at 30 to 70°C and within 6 to 10 hours.
9. Process according to claim 1, wherein the reaction of the condensation product with an amine is performed within 25 to hours. : - 10. Process according to claim 1, wherein the reaction product is isolated by treating with toluene, trifluoro-
’ PCT/EP99/09089 methylbenzene or diethoxymethane the residue that is obtained after the reaction solution has been concentrated by evaporation.
11. A process according to claim 1, substantially as herein described and illustrated.
12. A new process for the production of a compound, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19856481A DE19856481C1 (en) | 1998-12-02 | 1998-12-02 | Process for the production of cycles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200105406B true ZA200105406B (en) | 2002-07-25 |
Family
ID=7890308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200105406A ZA200105406B (en) | 1998-12-02 | 2001-06-29 | Method of producing cyclene. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1135376B1 (en) |
| JP (1) | JP4636690B2 (en) |
| KR (1) | KR100639270B1 (en) |
| CN (1) | CN1155583C (en) |
| AT (1) | ATE250042T1 (en) |
| AU (1) | AU764260B2 (en) |
| CA (1) | CA2353680C (en) |
| CZ (1) | CZ300157B6 (en) |
| DE (2) | DE19856481C1 (en) |
| DK (1) | DK1135376T3 (en) |
| ES (1) | ES2209530T3 (en) |
| HK (1) | HK1044148B (en) |
| IL (1) | IL143079A (en) |
| NO (1) | NO318054B1 (en) |
| NZ (1) | NZ512051A (en) |
| PT (1) | PT1135376E (en) |
| SK (1) | SK285372B6 (en) |
| WO (1) | WO2000032581A1 (en) |
| ZA (1) | ZA200105406B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2830253B1 (en) | 2001-09-28 | 2005-02-04 | Air Liquide | NOVEL PROCESS FOR THE PREPARATION OF C-FUNCTIONALIZED NITROGEN MACROCYCLES AND NOVEL INTERMEDIATES OBTAINED |
| CN103360333B (en) * | 2013-07-22 | 2016-03-30 | 厦门市华兴化工有限公司 | A kind of preparation method of high purity methyl-isochondodendrine |
| CN106490298B (en) * | 2016-11-28 | 2020-05-22 | 华南理工大学 | A kind of high dispersibility vegetable protein and preparation method thereof |
| US10344115B2 (en) | 2017-05-25 | 2019-07-09 | International Business Machines Corporation | Amine glyoxal resins |
| KR20190108383A (en) | 2018-03-14 | 2019-09-24 | 주식회사 지에이치바이오텍 | Novel synthesis of cyclen using oxamide and lithium aluminium hydride |
| EP4067348A1 (en) | 2021-03-30 | 2022-10-05 | Bracco Imaging SPA | Process for the preparation of cyclen |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9504922D0 (en) * | 1995-03-10 | 1995-04-26 | Nycomed As | Process |
| IT1284046B1 (en) * | 1996-06-21 | 1998-05-08 | Bracco Spa | PROCESS FOR THE PREPARATION OF TETRAAZAMACROCYCLES |
| IT1290457B1 (en) * | 1997-04-04 | 1998-12-03 | Bracco Spa | PROCESS FOR THE PREPARATION OF TETRAAZAMACROCYCLES |
| IT1291673B1 (en) * | 1997-04-28 | 1999-01-19 | Bracco Spa | PROCESS FOR THE PREPARATION OF 1,4,7,10 - TETRAAZACICLODODECANO |
-
1998
- 1998-12-02 DE DE19856481A patent/DE19856481C1/en not_active Expired - Lifetime
-
1999
- 1999-11-17 AT AT99959326T patent/ATE250042T1/en active
- 1999-11-17 CA CA002353680A patent/CA2353680C/en not_active Expired - Fee Related
- 1999-11-17 CZ CZ20011915A patent/CZ300157B6/en not_active IP Right Cessation
- 1999-11-17 SK SK724-2001A patent/SK285372B6/en not_active IP Right Cessation
- 1999-11-17 KR KR1020017006832A patent/KR100639270B1/en not_active Expired - Fee Related
- 1999-11-17 ES ES99959326T patent/ES2209530T3/en not_active Expired - Lifetime
- 1999-11-17 JP JP2000585223A patent/JP4636690B2/en not_active Expired - Fee Related
- 1999-11-17 IL IL14307999A patent/IL143079A/en not_active IP Right Cessation
- 1999-11-17 HK HK02104835.9A patent/HK1044148B/en not_active IP Right Cessation
- 1999-11-17 NZ NZ512051A patent/NZ512051A/en not_active IP Right Cessation
- 1999-11-17 AU AU16543/00A patent/AU764260B2/en not_active Ceased
- 1999-11-17 PT PT99959326T patent/PT1135376E/en unknown
- 1999-11-17 DK DK99959326T patent/DK1135376T3/en active
- 1999-11-17 EP EP99959326A patent/EP1135376B1/en not_active Expired - Lifetime
- 1999-11-17 CN CNB998140635A patent/CN1155583C/en not_active Expired - Fee Related
- 1999-11-17 WO PCT/EP1999/009089 patent/WO2000032581A1/en not_active Ceased
- 1999-11-17 DE DE59907056T patent/DE59907056D1/en not_active Expired - Lifetime
-
2001
- 2001-06-01 NO NO20012703A patent/NO318054B1/en not_active IP Right Cessation
- 2001-06-29 ZA ZA200105406A patent/ZA200105406B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010080648A (en) | 2001-08-22 |
| PT1135376E (en) | 2004-02-27 |
| EP1135376B1 (en) | 2003-09-17 |
| NO20012703L (en) | 2001-06-01 |
| SK7242001A3 (en) | 2001-12-03 |
| ES2209530T3 (en) | 2004-06-16 |
| EP1135376A1 (en) | 2001-09-26 |
| WO2000032581A1 (en) | 2000-06-08 |
| NO20012703D0 (en) | 2001-06-01 |
| SK285372B6 (en) | 2006-12-07 |
| KR100639270B1 (en) | 2006-10-27 |
| DE59907056D1 (en) | 2003-10-23 |
| DE19856481C1 (en) | 2000-07-06 |
| AU764260B2 (en) | 2003-08-14 |
| CZ20011915A3 (en) | 2001-09-12 |
| CZ300157B6 (en) | 2009-02-25 |
| HK1044148B (en) | 2005-04-01 |
| CN1329603A (en) | 2002-01-02 |
| CA2353680A1 (en) | 2000-06-08 |
| AU1654300A (en) | 2000-06-19 |
| ATE250042T1 (en) | 2003-10-15 |
| IL143079A0 (en) | 2002-04-21 |
| IL143079A (en) | 2005-08-31 |
| JP2003522114A (en) | 2003-07-22 |
| NO318054B1 (en) | 2005-01-24 |
| DK1135376T3 (en) | 2004-01-19 |
| JP4636690B2 (en) | 2011-02-23 |
| CA2353680C (en) | 2008-09-09 |
| CN1155583C (en) | 2004-06-30 |
| HK1044148A1 (en) | 2002-10-11 |
| NZ512051A (en) | 2003-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009185077A (en) | Method for producing 1,4,7,10-tetraazacyclododecane | |
| AU764260B2 (en) | Method of producing cyclene | |
| CZ304573B6 (en) | Lithium complexes of N- (1-hydroxymethyl-2,3-dihydroxypropyl) -1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and a process for the preparation of these lithium complexes and gadobutrol | |
| US6156890A (en) | Process for the production of cyclene | |
| WO2017094031A2 (en) | Novel process for preparation of apremilast | |
| JP2006527241A (en) | Cis-8B-methyldecahydro-2A, 4A, 6A, 8A-tetraazacyclopenta [FG] acenaphthylene, cis-decahydro-2A, 4A, 6A, 8A-tetraazacyclopenta [FG] acenaphthylene, cyclen and functionalization Cyclen | |
| KR100614535B1 (en) | Method for preparing 1,4,7,10-tetraazacyclododecane | |
| Thorn et al. | Synthesis of the potentially cytotoxic compound 5-[bis (2-chloroethyl) amino]-1, 3-phenylene biscarbamate | |
| GB1574043A (en) | Dextrorotatory propanones | |
| JP3088561B2 (en) | Method for producing 2,3-diaminopyridines | |
| JP2001522362A (en) | Method for producing 1,4,7,10-tetraazacyclododecane | |
| KR100809159B1 (en) | Improved Manufacturing Method of Rosatan | |
| US3915985A (en) | Process for preparing naphth{8 1,2-d{9 imidazole and intermediate therefor 1-hydroxynaphth{8 1,2-d{9 imidazole hydrate | |
| JPS61172846A (en) | Method of optical resolution of (+-)-2-chloroprorionic acid | |
| ES2354590T3 (en) | METHOD FOR THE PREPARATION OF ZOLMITRIPTANE. | |
| JPH01160969A (en) | Separation method for 2-substituted imidazoles | |
| JPS62164646A (en) | Optical resolution of (+-)-2-methylpentanoic acid | |
| CA2610665A1 (en) | Hydrates of alkaline-earth salts of irbesartan and the preparation thereof | |
| JPH02240073A (en) | Production of optically active pantolactone | |
| Grandberg | Synthesis of indolylalkylamines and related compounds from-, δ-halocarbonyls and arylhydrazines | |
| NO130475B (en) | ||
| WO2010069397A1 (en) | Process for the preparation of diclofenac epolamine |